Patients were randomly provided either darbepoetin alfa or placebo. In the darbepoetin alfa group, 50.7 % of the patients experienced loss of life from any hospitalization or cause for worsening heart failure. In the placebo group, 49.5 % of the patients experienced similar clinical outcomes. The trial was funded by Amgen, the maker of darbepoetin alfa . Related StoriesBoston Children's Hospital selects Vijay G. Sankaran to receive Rising Star AwardStudents released to da Vinci Robotic Medical Program at Saint Francis Memorial HospitalLoyola Medication, Palos Community Hospital jointly release innovative telemedicine program ‘This landmark study provides answers to caregivers who treat patients with heart failure complicated by anemia,’ stated James Young, M.D., cardiologist and Chair of the Cleveland Clinic Endocrinology & Metabolism Institute, and co-investigator of the RED-HF trial.Faulder, M.D., Brendan S. Steinfort, M.D., Miriam Priglinger, M.D., Timothy Ang, M.D., Rebecca Scroop, M.D., P. Alan Barber, M.D., Ben McGuinness, M.D., Tissa Wijeratne, M.D., Thanh G. Phan, M.D., Winston Chong, M.D., Ronil V. Chandra, M.D., Christopher F. Bladin, M.D., Monica Badve, M.D., Henry Rice, M.D., Laetitia de Villiers, M.D., Henry Ma, M.D., Patricia M. Desmond, M.D., Geoffrey A. Donnan, M.D., and Stephen M. Davis, M.D. For the EXTEND-IA Investigators: Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection The results of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands trial,1 which showed reduced disability among patients with ischemic stroke who were treated with endovascular thrombectomy furthermore to standard care, represent an advance in stroke care.